Claims
- 1. A 2-RR'N-5-PY-6-Q-nicotinamide having the formula ##STR5## where Q is hydrogen or lower-alkyl, R is lower-alkyl, lower-hydroxyalkyl, lower-alkoxyalkyl or Y-NB where Y is lower-alkylene having at least two carbon atoms between its connecting linkages, R' is hydrogen or methyl and PY is 4- or 3-pyridinyl or 4- or 3-pyridinyl having one or two lower-alkyl substituents, or pharmaceutically acceptable acid-addition salt thereof.
- 2. A compound according to claim 1 where PY is 4-pyridinyl or 3-pyridinyl, R is methyl, ethyl, 2-hydroxyethyl or 2-hydroxypropyl, R' is hydrogen or methyl and Q is hydrogen, methyl or ethyl.
- 3. 2-(2-Hydroxyethylamino)-5-(4-pyridinyl)nicotinamide or pharmaceutically acceptable acid-addition salt thereof.
- 4. 2-(2-Hydroxypropylamino)-5-(4-pyridinyl)nicotinamide or pharmaceutically acceptable acid-addition salt thereof.
- 5. 2-Methylamino-5-(4-pyridinyl)nicotinamide or pharmaceutically acceptable acid-addition salt thereof.
- 6. A cardiotonic composition for increasing cardiac contractility, said composition comprising a pharmaceutically acceptable inert carrier and, as the active component thereof, a cardiotonically effective amount of 2-RR'N-5-PY-6-Q-nicotinamide or pharmaceutically acceptable acid-addition salt thereof, where Q is hydrogen or lower-alkyl, R is lower-alkyl, lower-hydroxyalkyl, lower-alkoxyalkyl or Y-NB where Y is lower-alkylene having at least two carbon atoms between its connecting linkages, R' is hydrogen or methyl and PY is 4- or 3-pyridinyl or 4- or 3-pyridinyl having one or two lower-alkyl substituents.
- 7. A composition according to claim 6, where PY is 4-pyridinyl or 3-pyridinyl, R is methyl, ethyl, 2-hydroxyethyl or 2-hydroxypropyl, R' is hydrogen or methyl and Q is hydrogen, methyl or ethyl.
- 8. A composition according to claim 6 where the active component is 2-methylamino-5-(4-pyridinyl)nicotinamide or pharmaceutically-acceptable acid-addition thereof.
- 9. The method for increasing cardiac contractility in a patient requiring such treatment which comprises administering orally or parenterally in a solid or liquid dosage form to such patient said cardiotonic composition of claim 6.
- 10. The method for increasing cardiac contractility in a patient requiring such treatment which comprises administering orally or parenterally in a solid or liquid dosage form to such patient said cardiotonic composition of claim 7.
- 11. The method for increasing cardiac contractility in a patient requiring such treatment which comprises administering orally or parenterally in a solid or liquid dosage form to such patient said cardiotonic composition of claim 8.
CROSS-REFERENCE TO RELATED APPLICATIONS
Copending applications Ser. Nos. 135,105, filed Mar. 28, 1980 and now U.S. Pat. No. 4,294,837, issued Oct. 13, 1981, and 236,147, filed Feb. 20, 1981 as a division of Ser. No. 135,105 and now U.S. Pat. No. 4,309,537, issued Jan. 5, 1982, show the preparation of cardiotonically active 1,3-dihydro-1(or 3)-substituted-6-(pyridinyl)-2H-imidazo[4,5-b]pyridin-2-ones by reacting a 5-(pyridinyl)pyridine-2,3-diamine derivative with urea or carbonyldiimidazole.
US Referenced Citations (4)
Number |
Name |
Date |
Kind |
4107315 |
Lesher et al. |
Aug 1978 |
|
4264603 |
Lesher et al. |
Apr 1981 |
|
4264612 |
Lesher et al. |
Apr 1981 |
|
4297360 |
Lesher et al. |
Oct 1981 |
|
Non-Patent Literature Citations (1)
Entry |
Baldwin et al., J. Med. Chem. 20, 1189-1193, (1977). |